NEDD9 is a positive regulator of epithelial-mesenchymal transition and promotes invasion in aggressive breast cancer

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Kong, Chenfei ^a   Wang, Changqing ^b   Wang, Liping ^c   Ma, Musong ^b   Niu, Chunbo ^c   Sun, Xiaoqian ^a   Du, Juan ^a   Dong, Zhixiong ^a   Zhu, Shan ^a   Lu, Jun ^a   Huang, Baiqu ^a  

^a NORTHEAST NORMAL UNIVERSITY   (China)

^b The Breast Surgery   (China)

^c JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FIBRONECTIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; NEDD9 PROTEIN; NERVE CELL ADHESION MOLECULE; OCCLUDIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; CADHERIN; LUCIFERASE; NEDD9 PROTEIN, HUMAN; PHOSPHOPROTEIN; PROGESTERONE RECEPTOR; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SNAIL FAMILY TRANSCRIPTION FACTORS; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL CULTURE; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; BREAST; BREAST TUMOR; CELL ADHESION; CELL MOTION; CHROMATIN IMMUNOPRECIPITATION; CLONOGENIC ASSAY; COMPARATIVE STUDY; FEMALE; GENETICS; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WOUND HEALING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BLOTTING, WESTERN; BREAST; BREAST NEOPLASMS; CADHERINS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; COLONY-FORMING UNITS ASSAY; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; LUCIFERASES; MAP KINASE SIGNALING SYSTEM; NEOPLASM INVASIVENESS; PHOSPHOPROTEINS; PROMOTER REGIONS, GENETIC; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; WOUND HEALING;

EID: 79960888055     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022666     Document Type: Article

References (47)

1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
2. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874.
3. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100: 8418-8423.
4. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, et al. (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10: 5367-5374.
5. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, et al. (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24: 5652-5657.
6. Cleator S, Heller W, Coombes RC, (2007) Triple-negative breast cancer: therapeutic options. Lancet Oncol 8: 235-244.
7. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V, (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109: 1721-1728.
8. Gupta GP, Perk J, Acharyya S, de Candia P, Mittal V, et al. (2007) ID genes mediate tumor reinitiation during breast cancer lung metastasis. Proc Natl Acad Sci U S A 104: 19506-19511.
9. Wang Y, Zhang H, Chen Y, Sun Y, Yang F, et al. (2009) LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell 138: 660-672.
10. Mani SA, Yang J, Brooks M, Schwaninger G, Zhou A, et al. (2007) Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci U S A 104: 10069-10074.
11. Yu M, Smolen GA, Zhang J, Wittner B, Schott BJ, et al. (2009) A developmentally regulated inducer of EMT, LBX1, contributes to breast cancer progression. Genes Dev 23: 1737-1742.
12. Fidler IJ, (2003) The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 3: 453-458.
13. Thiery JP, Sleeman JP, (2006) Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7: 131-142.
14. Thiery JP, (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442-454.
15. Thiery JP, Chopin D, (1999) Epithelial cell plasticity in development and tumor progression. Cancer Metastasis Rev 18: 31-42.
16. Savagner P, Boyer B, Valles AM, Jouanneau J, Thiery JP, (1994) Modulations of the epithelial phenotype during embryogenesis and cancer progression. Cancer Treat Res 71: 229-249.
17. Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J, (2003) Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci U S A 100: 8430-8435.
18. Nelson WJ, Nusse R, (2004) Convergence of Wnt, beta-catenin, and cadherin pathways. Science 303: 1483-1487.
19. Timmerman LA, Grego-Bessa J, Raya A, Bertran E, Perez-Pomares JM, et al. (2004) Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev 18: 99-115.
20. Yang J, Weinberg RA, (2008) Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14: 818-829.
21. Natarajan M, Stewart JE, Golemis EA, Pugacheva EN, Alexandropoulos K, et al. (2006) HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells. Oncogene 25: 1721-1732.
22. Kim M, Gans JD, Nogueira C, Wang A, Paik JH, et al. (2006) Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 125: 1269-1281.
23. Izumchenko E, Singh MK, Plotnikova OV, Tikhmyanova N, Little JL, et al. (2009) NEDD9 promotes oncogenic signaling in mammary tumor development. Cancer Res 69: 7198-7206.
24. Wang X, Pan L, Feng Y, Wang Y, Han Q, et al. (2008) P300 plays a role in p16(INK4a) expression and cell cycle arrest. Oncogene 27: 1894-1904.
25. Gumireddy K, Li A, Gimotty PA, Klein-Szanto AJ, Showe LC, et al. (2009) KLF17 is a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer. Nat Cell Biol 11: 1297-1304.
26. Xia D, Holla VR, Wang D, Menter DG, DuBois RN, (2010) HEF1 is a crucial mediator of the proliferative effects of prostaglandin E(2) on colon cancer cells. Cancer Res 70: 824-831.
27. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, et al. (2006) Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19: 264-271.
28. Moyano JV, Evans JR, Chen F, Lu M, Werner ME, et al. (2006) AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest 116: 261-270.
29. Verlinden L, Vanden Bempt I, Eelen G, Drijkoningen M, Verlinden I, et al. (2007) The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor/progesterone receptor/HER-2 breast carcinomas. Cancer Res 67: 6574-6581.
30. Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, et al. (2007) Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat 105: 319-326.
31. Rahman M, Davis SR, Pumphrey JG, Bao J, Nau MM, et al. (2009) TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res Treat 113: 217-230.
32. Zheng M, McKeown-Longo PJ, (2002) Regulation of HEF1 expression and phosphorylation by TGF-beta 1 and cell adhesion. J Biol Chem 277: 39599-39608.
33. Giampieri S, Manning C, Hooper S, Jones L, Hill CS, et al. (2009) Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol 11: 1287-1296.
34. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, et al. (2008) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10: 593-601.
35. Jorda M, Olmeda D, Vinyals A, Valero E, Cubillo E, et al. (2005) Upregulation of MMP-9 in MDCK epithelial cell line in response to expression of the Snail transcription factor. J Cell Sci 118: 3371-3385.
36. Peinado H, Ballestar E, Esteller M, Cano A, (2004) Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell Biol 24: 306-319.
37. Montserrat N, Gallardo A, Escuin D, Catasus L, Prat J, et al. (2011) Repression of E-cadherin by SNAIL, ZEB1, and TWIST in invasive ductal carcinomas of the breast: a cooperative effort? Hum Pathol 42: 103-110.
38. von Burstin J, Eser S, Paul MC, Seidler B, Brandl M, et al. (2009) E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastroenterology 137: 361-371, 371 e361-365.
39. Chua HL, Bhat-Nakshatri P, Clare SE, Morimiya A, Badve S, et al. (2007) NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene 26: 711-724.
40. Conacci-Sorrell M, Simcha I, Ben-Yedidia T, Blechman J, Savagner P, et al. (2003) Autoregulation of E-cadherin expression by cadherin-cadherin interactions: the roles of beta-catenin signaling, Slug, and MAPK. J Cell Biol 163: 847-857.
41. Barbera MJ, Puig I, Dominguez D, Julien-Grille S, Guaita-Esteruelas S, et al. (2004) Regulation of Snail transcription during epithelial to mesenchymal transition of tumor cells. Oncogene 23: 7345-7354.
42. Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, et al. (2007) LKB1 modulates lung cancer differentiation and metastasis. Nature 448: 807-810.
43. Simpson KJ, Selfors LM, Bui J, Reynolds A, Leake D, et al. (2008) Identification of genes that regulate epithelial cell migration using an siRNA screening approach. Nat Cell Biol 10: 1027-1038.
44. Fashena SJ, Einarson MB, O'Neill GM, Patriotis C, Golemis EA, (2002) Dissection of HEF1-dependent functions in motility and transcriptional regulation. J Cell Sci 115: 99-111.
45. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, et al. (2006) X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9: 121-132.
46. Storci G, Sansone P, Trere D, Tavolari S, Taffurelli M, et al. (2008) The basal-like breast carcinoma phenotype is regulated by SLUG gene expression. J Pathol 214: 25-37.
47. Shin S, Dimitri CA, Yoon SO, Dowdle W, Blenis J, (2010) ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. Mol Cell 38: 114-127.